Intuitive Surgical (NASDAQ:ISRG) Director Craig Barratt Sells 750 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Craig Barratt sold 750 shares of Intuitive Surgical stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $580.00, for a total transaction of $435,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Intuitive Surgical Price Performance

Shares of ISRG stock traded down $9.26 on Friday, reaching $556.26. 357,722 shares of the company were exchanged, compared to its average volume of 2,115,559. The company has a 50-day moving average of $480.86 and a 200-day moving average of $502.93. The company has a market cap of $199.40 billion, a price-to-earnings ratio of 73.73, a PEG ratio of 4.94 and a beta of 1.62. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The firm had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm earned $1.84 EPS. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Argus upped their target price on Intuitive Surgical from $600.00 to $630.00 in a report on Monday, October 27th. Erste Group Bank reissued a “hold” rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Wells Fargo & Company raised their target price on Intuitive Surgical from $599.00 to $600.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Robert W. Baird set a $655.00 price target on shares of Intuitive Surgical in a report on Wednesday, October 22nd. Finally, Mizuho set a $575.00 price objective on shares of Intuitive Surgical in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $608.92.

Hedge Funds Weigh In On Intuitive Surgical

Large investors have recently made changes to their positions in the stock. Brighton Jones LLC grew its holdings in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after buying an additional 731 shares in the last quarter. Larson Financial Group LLC grew its stake in Intuitive Surgical by 8.8% during the first quarter. Larson Financial Group LLC now owns 4,456 shares of the medical equipment provider’s stock valued at $2,207,000 after acquiring an additional 359 shares in the last quarter. Bridgewater Advisors Inc. purchased a new stake in Intuitive Surgical in the 1st quarter worth approximately $459,000. DDD Partners LLC purchased a new stake in shares of Intuitive Surgical in the first quarter worth $318,000. Finally, Cullen Frost Bankers Inc. grew its position in Intuitive Surgical by 1.8% during the first quarter. Cullen Frost Bankers Inc. now owns 77,382 shares of the medical equipment provider’s stock worth $38,325,000 after buying an additional 1,387 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.